Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: an international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial)

Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: an international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial)

Abstract Background Radiotherapy (RT) following breast-conserving surgery (BCS) is mainly used to decrease the rate of ipsilateral breast tumor recurrence (IBTR) in women with breast ductal carcinoma in situ (DCIS). Recent studies have demonstrated that low-dose tamoxifen significantly reduces IBTR...

Full description

Bibliographic Details
Main Authors: Sung-Hsin Kuo, Ling-Ming Tseng, Shou-Tung Chen, Yasuaki Sagara, Yuan-Ching Chang, Hsien-Tang Yeh, Yao-Lung Kuo, Chih-Chiang Hung, Tzu-Pin Lu, Yi-Hsuan Lee, Masakazu Toi, Chiun-Sheng Huang
Format: Article
Language:English
Published: BMC 2023-09-01
Series:BMC Cancer
Subjects:
Ductal carcinoma in situ
Breast
Tamoxifen
Radiotherapy
Low-risk
Online Access:https://doi.org/10.1186/s12885-023-11291-6

Internet

https://doi.org/10.1186/s12885-023-11291-6

Similar Items